NEW YORK, Oct. 10, 2019 /PRNewswire/ -- Oppenheimer
& Co. Inc. ("Oppenheimer") – a leading investment bank,
wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE:
OPY) – will host its Houston Oncology Summit on October 17, 2019 at the University of Texas MD Anderson Cancer Center.
The agenda includes presentations from notable scientists and
researchers at MD Anderson and leading oncology companies.
Additionally, the dinner reception will feature The Checkmates, a
band of top MD Anderson surgeons and executives, who will perform
live to raise funds for MD Anderson's Children's Cancer
Hospital.
Oppenheimer is honored to help raise funds for the hospital and
will be directing all donations from the summit to the pediatric
oncology center at MD Anderson. Cancer is the leading cause of
death by disease for children in the
United States and MD Anderson Children's Cancer Hospital was
the first pediatric oncology intensive care center in the US and
continues to provide treatments and drugs for children with cancer
that are not provided anywhere else. More information on donating
can be found here.
"This exciting event represents another example of our
commitment to deliver opportunities for dialogue between investors,
companies and KOLs in unique settings. Topping off the day will be
a special performance by The Checkmates to raise money for MD
Anderson's Children's Cancer Hospital," said Michael Margolis, R.Ph., Managing Director and
Co-Head of Healthcare Investment Banking. "The hospital's mission
is to give hope to those battling cancer and provide the best
possible care for children, while supporting the entire family and
the money we raise on October 17 will
help those battling this devastating disease."
Company presentations include Bellicum Pharmaceuticals,
Immuneering, Marker Therapeutics, Iovance, Cue Biopharma, Gamida
Cell and Tvardi Therapeutics. Additionally, several esteemed MD
Anderson faculty members will offer insights on important trends in
oncology, including:
- Jennifer Wargo, M.D., M.M.Sc –
Associate Professor, Department of Surgical Oncology &
Department of Genomic Medicine
- Philip Jones, Ph.D. – VP,
Therapeutics Discovery, Institute for Applied Cancer Science
(IACS)
- Katy Rezvani, M.D., Ph.D. –
Professor, Department of Stem Cell Transplantation, Director of
Translational Research
- Eduardo Vilar-Sanchez, M.D.,
Ph.D. – Associate Professor, Department of Clinical Cancer
Prevention
- Hussein Tawbi, M.D., Ph.D. –
Associate Professor, Department of Melanoma Medical Oncology,
Director of Melanoma Clinical Research and Early Drug
Development
- Elizabeth Burton, MBA –
Director, Research Planning & Development, Surgical
Oncology
- Ferran Prat, Ph.D., J.D. – Vice
President of Strategic Industry Ventures
"Providing our clients access to innovative oncology companies
allows them to better understand what's driving this important
industry," added Erica L. Moffett,
Managing Director and Associate Director of Research at
Oppenheimer. "Our goal is to foster collaboration between smart
investors and the companies paving the way in terms of oncology
research, development and treatments."
Oppenheimer life sciences analysts include:
- Matt Biegler, Senior Analyst
covering Emerging Biotechnology
- Mark Breidenbach, Ph.D.,
Executive Director and Senior Analyst covering Biotechnology
- Kevin DeGeeter, Managing
Director and Senior Analyst covering Biotechnology
- Leland Gershell, M.D., Ph.D,
Managing Director and Senior Analyst covering Biotechnology
- Justin Kim, Senior Analyst
covering Biotechnolog
- Jay Olson, Managing Director and
Senior Analyst covering Biopharmaceuticals
- Esther Rajavelu, Executive
Director and Senior Analyst covering Biotech and Specialty
Pharmaceuticals
- Hartaj Singh, Managing Director and Senior Analyst covering
Biotechnology
- Silvan Tuerkcan, Ph.D., Senior Analyst covering
Biotechnology
Upcoming Oppenheimer events include the FinTech, Blockchain
& AI: Disruptive Innovation Summit on November 12, 2019 in San Francisco, CA, and the 30th
Annual Healthcare Conference on March 17-18,
2020.
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc.
(Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), and its affiliates provide a
full range of wealth management, securities brokerage and
investment banking services to high-net-worth individuals,
families, corporate executives, local governments, businesses and
institutions.
View original
content:http://www.prnewswire.com/news-releases/oppenheimer-to-host-houston-oncology-summit-at-the-university-of-texas-md-anderson-cancer-center-300936355.html
SOURCE Oppenheimer & Co. Inc.